<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=Pelai</id>
	<title>Pelai - Revision history</title>
	<link rel="self" type="application/atom+xml" href="http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=Pelai"/>
	<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=Pelai&amp;action=history"/>
	<updated>2026-10-05T09:11:08Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.31.0</generator>
	<entry>
		<id>http://hboevidence.wikis.unsw.edu.au/index.php?title=Pelai&amp;diff=184&amp;oldid=prev</id>
		<title>Gordoben: Imported from Wikispaces</title>
		<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=Pelai&amp;diff=184&amp;oldid=prev"/>
		<updated>2018-01-22T06:14:34Z</updated>

		<summary type="html">&lt;p&gt;Imported from Wikispaces&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 130%;&amp;quot;&amp;gt;'''N-acetylcysteine administration prevented a rise in thiobarbituric acid reactive substance (TBARS) following hyperbaric oxygen therapy.''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Clinical Bottom Line:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. Evidence that the plasma concentration of a marker of oxygen free radical stress is not raised in patients who are given N-acetylcysteine during their course of hyperbaric oxygen. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Appraised by:''' Mike Bennett, Dept. of Diving and Hyperbaric Medicine, Prince of Wales Hospital &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Sydney; Thursday, 22 July 1999 &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Clinical Scenario:''' A patient receiving hyperbaric oxygen therapy. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Three-part Question:''' When patients are undergoing hyperbaric oxygen therapy, does the administration of N-acetylcysteine reduce the extent of lipid peroxidation of the tissues that results from oxygen radical damage? &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Search Terms:''' Hyperbaric oxygenation, oxygen free radicals, N-acetylcysteine. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Study:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Non-blinded randomised controlled trial with intention-to-treat. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Patients having hyperbaric oxygen therapy for a range of conditions (non-acute and non-infective). &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Control group''' (N = 10; 10 analysed): HBO at 2.2 ATA for 90 minutes daily, five days each week to a total of twenty treatments. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Experimental group''' (N = 7; 7 analysed): As above, but patients also received 1800mg N-acetylcysteine daily. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Evidence:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| &lt;br /&gt;
| &amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;color: black;&amp;quot;&amp;gt;Non-Event Outcomes&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: Arial,Helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;color: black;&amp;quot;&amp;gt;Time to outcome&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: Arial,Helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;color: black;&amp;quot;&amp;gt;HBO group&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: Arial,Helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;color: black;&amp;quot;&amp;gt;HBO and NAC group&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: Arial,Helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;color: black;&amp;quot;&amp;gt;P-value&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;color: black;&amp;quot;&amp;gt;Thio-barbituric acid reactive substance (microm/l)&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;color: #000000; display: block; font-family: Arial,Helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;4 weeks&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;color: #000000; display: block; font-family: Arial,Helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;2.18&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;color: #000000; display: block; font-family: Arial,Helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;1.38&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;color: #000000; display: block; font-family: Arial,Helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;&amp;lt;0.01&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;br&amp;gt;&amp;lt;span style=&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;br&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''&amp;lt;span style'''&amp;quot;color: black;&amp;quot;&amp;gt;TBARS change over treatment period&amp;lt;/span&amp;gt;'''&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;color: #000000; display: block; font-family: Arial,Helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;4 weeks&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;color: #000000; display: block; font-family: Arial,Helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;1.02&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;color: #000000; display: block; font-family: Arial,Helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-0.16&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;color: #000000; display: block; font-family: Arial,Helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;not given&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Comments:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. Apparently no attempt to blind patients, although it is difficult to see how this might affect the result. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. The clinical significance of this finding is unknown, but the authors remark that there was no clinical evidence of harm. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;3. No mention of side-effects of the N-acetylcysteine administration in the abstract. (Full text available only in Italian). &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Expiry date:''' January 2022&amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''References:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. Peliai P, Rocco M, De Blasi R, Spadetta G, Alampi D, Araimo F, Nicolucci S. Assessment of lipid peroxidation in hyperbaric oxygen therapy: protective role of N-acetylcysteine. Minerva Anestesiologia 1995; 61:133-139. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:sumhorsa.gif|center]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color: #7c00ff; display: block; font-family: arial,helvetica,sans-serif; font-size: 26px; text-align: center;&amp;quot;&amp;gt;'''[[Physiology  |  BACK]]'''&amp;lt;/span&amp;gt;&amp;lt;span style=&amp;quot;color: #7c00ff; display: block; font-family: arial,helvetica,sans-serif; font-size: 26px; text-align: center;&amp;quot;&amp;gt;&lt;br /&gt;
&amp;lt;/span&amp;gt;&amp;lt;span style=&amp;quot;color: #7c00ff; display: block; font-family: arial,helvetica,sans-serif; font-size: 26px; text-align: center;&amp;quot;&amp;gt;&lt;br /&gt;
&amp;lt;/span&amp;gt;&lt;/div&gt;</summary>
		<author><name>Gordoben</name></author>
		
	</entry>
</feed>